Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
about
Adverse effects of medical cannabinoids: a systematic reviewCannabinoids and Epilepsy.Role of cannabinoids in multiple sclerosisCannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survivalRole of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiolCannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsidePain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids.Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter SurveyThe endocannabinoid system as a target for the treatment of neurodegenerative disease.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.The pharmacologic and clinical effects of medical cannabis.Therapeutic potential of cannabinoid medicines.Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts.Medical Marijuana: Just the Beginning of a Long, Strange Trip?Treating pain in multiple sclerosis.Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms.Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the EvidenceMechanisms and pharmacology of neuropathic pain in multiple sclerosis.Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.The analgesic potential of cannabinoids.Cannabinoids in the management of spasticity associated with multiple sclerosis.Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokersManaging neuropathic pain with Sativex: a review of its pros and cons.Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE modelsTherapeutic benefits of cannabis: a patient survey.The multiplicity of action of cannabinoids: implications for treating neurodegeneration.THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.Recent advances in the pharmaceutical management of pain.Cannabinoids, multiple sclerosis and neuroprotection.Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.Pain and multiple sclerosis: pathophysiology and treatment.Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.Emerging Treatments for Neuropathic Pain.Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.
P2860
Q24644380-9726E7B0-9E2A-4E6D-BAFA-E2BAF9E5DE4BQ27336451-3BAF66BA-7AE0-46EB-8AF0-F578B2D86A17Q28305413-55082AD4-4DEB-4417-9835-E78480AE8209Q33590580-230FACC9-F91D-4FB1-AE11-DA75530FF0EFQ33869556-AAF6DA2E-658D-41AC-A43C-9589C4F725D1Q34019573-DB13A302-9EDF-4D69-9200-A120E45428D8Q34033859-797379BE-BFBB-495B-8D90-C9136AD96993Q34077887-1705D9B5-88A3-4786-9A7C-0EDB1F24683FQ34098196-47CFE7DE-A875-4C39-9AE4-11C2B2A3C3A7Q34110857-8A0B9D71-1B4F-4090-BB42-18D81B8D48EEQ34139377-5DCF1BFC-A299-464F-B230-11054822F633Q34219132-FC9460B8-4BDC-4143-9BAA-CB94D3BFB849Q34326515-B65155FB-1760-4100-A543-CEE30D5600BDQ34368715-CCFF70FB-4601-4007-AB29-1FF2A94EC6C8Q34468292-547B6613-9BBF-40FE-AFDE-1DFBB630CE12Q34540978-CAEA6F4D-8538-4F2C-839A-48B65911746FQ34632301-16376812-E335-48DA-8230-167B8BCDA803Q34801735-E25610CB-736A-435E-B237-4216665D83FCQ35647941-7301E32F-7514-41CB-9746-76748BC103F2Q35731415-1D31A5E1-8F99-413C-BA48-B19F3EA46739Q35893522-A5212C94-46B7-4865-8DC6-79CDAC619527Q36618089-15159199-FC82-4EE2-BFDF-F69D15AE1BBDQ37057325-E6AC6C0D-0538-473C-A458-D73AB9A4180FQ37062594-8BD177C2-24D0-4D05-B776-CE06EFEFDFA2Q37077524-9E5AC034-991F-449A-A82D-FD5344D72654Q37103395-EAE2FA65-C579-4F70-B8DD-811BFFFE0F1AQ37142074-3EA2EFC9-29B4-4355-B3F9-29D86AE5143BQ37575719-73DED851-9036-4183-84F5-F34EBAEB189DQ37601317-305BEF12-8960-46AC-992B-4948C4162B66Q37720851-54D8A038-4C6F-406E-8B0B-A591EEF62E75Q37793366-F5D0E5C0-9922-4129-B96B-EF703EF217B0Q37860314-6440F9B1-BF50-4573-B332-C8E95516C4CFQ37960192-FC225C96-81C5-4DFC-836C-A515E855691DQ37960199-EC081672-0F2B-4924-BFDC-AC23FDD74FB1Q38041231-E023EFAA-1B09-4EF6-92F0-0D40921CE5DDQ38068364-DAD936F1-4284-4C53-8CA9-44A63E566D26Q38102053-F5A80D21-4517-4C9D-BFB4-12BD3A947611Q38212376-6C1E9B46-93CC-4515-ABDE-D89F77F0F692Q38623570-0A2F3004-4F4F-4EBF-97A5-25D3A54D8C31Q38996589-8AE6CBCA-C91E-4A48-9702-81E0B9C430F2
P2860
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@ast
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@en
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@nl
type
label
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@ast
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@en
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@nl
prefLabel
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@ast
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@en
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@nl
P921
P1476
Oromucosal delta9-tetrahydroca ...... label, 2-year extension trial.
@en
P2093
David J Rog
Turo J Nurmikko
P304
P356
10.1016/J.CLINTHERA.2007.09.013
P577
2007-09-01T00:00:00Z